This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Nov;208(5):1054-1055.

doi: 10.1097/JU.0000000000002855.01. Epub 2022 Aug 10.

Editorial Comment

Alberto Bossi¹, Gustave Roussy², Gert De Meerleer³

Affiliations

Affiliations

¹ Amethyst Radiotherapy Group, Paris, France.
² Villejuif, France.
³ Department of Radiation Oncology, University Hospital Leuven, Leuven, Belgium.

PMID: 35947520
DOI: 10.1097/JU.0000000000002855.01

Editorial

Editorial Comment

Alberto Bossi et al. J Urol. 2022 Nov.

. 2022 Nov;208(5):1054-1055.

doi: 10.1097/JU.0000000000002855.01. Epub 2022 Aug 10.

Authors

Alberto Bossi¹, Gustave Roussy², Gert De Meerleer³

Affiliations

¹ Amethyst Radiotherapy Group, Paris, France.
² Villejuif, France.
³ Department of Radiation Oncology, University Hospital Leuven, Leuven, Belgium.

PMID: 35947520
DOI: 10.1097/JU.0000000000002855.01

No abstract available

PubMed Disclaimer

Comment on

Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
Mazzone E, Gandaglia G, Stabile A, Bravi CA, Barletta F, Scuderi S, Cirulli GO, Fossati N, Cucchiara V, Raggi D, Necchi A, Montorsi F, Briganti A. Mazzone E, et al. J Urol. 2022 Nov;208(5):1046-1055. doi: 10.1097/JU.0000000000002855. Epub 2022 Jul 5. J Urol. 2022. PMID: 35830554

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources